Treatment with a combination of anti-VEGFR2 and anti-PD-L1 antibodies induces HEV formation in pancreatic and breast tumor mouse models promoting simultaneously T cell infiltration and activation (161). This evidence concerns the gene KDR and breast neoplasm.